P. Papanastasiou
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Bone health and treatments, Bone health and osteoporosis research, Psoriasis: Treatment and Pathogenesis, Autoimmune and Inflammatory Disorders Research, Bone and Joint Diseases
Most-Cited Works
- → Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial(2009)527 cited
- → Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis(2010)355 cited
- → Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis(2012)350 cited
- → Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis(2006)152 cited
- → Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial(2020)93 cited
- → Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data(2022)88 cited
- → Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial(2017)57 cited
- → The variant-specific surface protein of Giardia, VSP4A1, is a glycosylated and palmitoylated protein(1997)48 cited
- → The Release of the Variant Surface Protein of Giardia to Its Soluble Isoform Is Mediated by the Selective Cleavage of the Conserved Carboxy-Terminal Domain(1996)37 cited
- → Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis(2011)32 cited